pharma · Alzheimer's Disease · Type 2 Diabetes Mellitus · VTVT
vTv Therapeutics
vTv Therapeutics clinical programs — 9 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 3980 Premier Dr, Suite 110, High Point, North Carolina 27265, US
- Employees
- 55
- Programs
- 14
- Drugs
- 2
- Patents
- 50
vTv Therapeutics projects
9 ClinicalTrials.gov programs sponsored by vTv Therapeutics.
vTv Therapeutics has 9 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Azeliragon
vTv Therapeutics
Alzheimer Disease
1 trial -
GK1-399 (formerly TTP399)
vTv Therapeutics
Type 2 Diabetes Mellitus
1 trial -
TTP054
vTv Therapeutics
Type 2 Diabetes Mellitus
1 trial -
TTP273
vTv Therapeutics
Type 2 Diabetes Mellitus
1 trial -
TTP399
vTv Therapeutics
Diabetes Mellitus, Type 1
1 trial -
TTP399 400 mg
vTv Therapeutics
Diabetes Mellitus, Type 2
1 trial -
TTP435
vTv Therapeutics
Obesity
1 trial -
TTP889
vTv Therapeutics
Coagulation
1 trial -
TTP889
vTv Therapeutics
Venous Thromboembolism
1 trial
Frequently asked questions
How many clinical projects does vTv Therapeutics have?
9 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.